Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 964 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Not listed Not applicable Interventional

Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease

NCT00932711
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Educational brochures
Behavioral
Lead sponsor
VA Midwest Health Care Network
Federal
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2009 · Synced Oct 14, 2026, 4:15 PM EDT
Completed No phase listed Observational

Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome

NCT01033266
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Interventions
CPET
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

NCT03937479
View directory record Official record
Conditions
COPD
Interventions
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
50
States / cities
Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Home Pulmonary Rehabilitation for COPD

NCT03480386
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions
Home Based Pulmonary Rehabilitation
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 99 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

NCT03639051
View directory record Official record
Conditions
COPD
Interventions
Targeted Lung Denervation (TLD), Optimal Medical Care
Device · Other
Lead sponsor
Nuvaira, Inc.
Industry
Eligibility
40 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

NCT00698828
View directory record Official record
Conditions
Cachexia
Interventions
Placebo comparator, SUN11031 20 μg/kg, SUN11031 40 μg/kg
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
50 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Waterbury, Connecticut • Clearwater, Florida • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 14, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

NCT07576894
View directory record Official record
Conditions
COPD, Pulmonary Hypertension, Exercise, Right Ventricular (RV) Dysfunction, Exercise Training
Interventions
Exercise training
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

NCT03516994
View directory record Official record
Conditions
Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions
Respecting Choices First Steps, Five Wishes Form
Behavioral
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Not applicable Interventional

A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD

NCT01985529
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Exercise
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 14, 2026, 4:15 PM EDT
Terminated No phase listed Interventional Results available

Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients

NCT03851510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Interventions
Vector ventilator, Resmon Pro
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

SGA for TEE: Safe Alternative to Deep Sedation for Patients With High-risk Cardiopulmonary Disease.

NCT04939220
View directory record Official record
Conditions
Cardiopulmonary Disease
Interventions
TEE with SGA, TEE with Deep Sedation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 14, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo
Drug
Lead sponsor
Expedition Therapeutics, Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Northridge, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)

NCT01349608
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Physical Activity, Health Behavior
Interventions
Telephonic health coaching
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01355978
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
Noninvasive Open Ventilation System
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Concord, California • San Diego, California • Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 14, 2026, 4:15 PM EDT
Completed No phase listed Observational

Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm

NCT07223749
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Recruiting No phase listed Observational

COPD Exacerbation Follow Up

NCT07118306
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
40 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Long-term Oxygen Treatment Trial

NCT00692198
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Supplemental oxygen therapy
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 14, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 14, 2026, 4:15 PM EDT